Ken Griffin Esperion Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 100,800 shares of ESPR stock, worth $83,664. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,800
Previous 37,700
167.37%
Holding current value
$83,664
Previous $82,000
76.83%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding ESPR
# of Institutions
200Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$11.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$9.53 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$9.07 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$8.05 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$5.75 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $55.2M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...